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ABSTRACT
Fatty acid synthase (FASN), a lipogenic enzyme, is upregulated in colorectal 
cancer (CRC). Increased de novo lipid synthesis is thought to be a metabolic 
adaptation of cancer cells that promotes survival and metastasis; however, the 
mechanisms for this phenomenon are not fully understood. We show that FASN 
plays a role in regulation of energy homeostasis by enhancing cellular respiration in 
CRC. We demonstrate that endogenously synthesized lipids fuel fatty acid oxidation, 
particularly during metabolic stress, and maintain energy homeostasis. Increased 
FASN expression is associated with a decrease in activation of energy-sensing 
pathways and accumulation of lipid droplets in CRC cells and orthotopic CRCs. 
Immunohistochemical evaluation demonstrated increased expression of FASN and 
p62, a marker of autophagy inhibition, in primary CRCs and liver metastases compared 
to matched normal colonic mucosa. Our findings indicate that overexpression of FASN 
plays a crucial role in maintaining energy homeostasis in CRC via increased oxidation 
of endogenously synthesized lipids. Importantly, activation of fatty acid oxidation 
and consequent downregulation of stress-response signaling pathways may be key 
adaptation mechanisms that mediate the effects of FASN on cancer cell survival and 
metastasis, providing a strong rationale for targeting this pathway in advanced CRC.
INTRODUCTION
The metabolic properties of cancer cells are 
remarkably different from those of normal cells [1]. 
An increased rate of lipid synthesis in cancer has been 
recognized as an important aspect of metabolism in 
transformed cells [2]. In contrast to normal epithelial cells, 
the majority of fatty acids in malignant cells are derived 
from de novo lipogenesis, regardless of the availability 
of extracellular lipids [3, 4]. Fatty acid synthase (FASN), 
a key enzyme of de novo lipid biosynthesis [5], is 
significantly unregulated in many cancers, including 
colorectal cancer (CRC) [6–8], and is associated 
with aggressive disease and a poor prognosis [9, 10]. 
Previously, we showed that the expression of FASN 
progressively increases with increased CRC stage [10]. 
Furthermore, our in vivo studies demonstrated that 
shRNA-mediated inhibition of FASN significantly reduces 
lung and hepatic metastases in nude mice and inhibits 
angiogenesis in an orthotopic CRC mouse model [9, 10]. 
Consistent with our findings, other studies have shown 
an association of de novo lipid synthesis with metastatic 
prostate cancer and melanoma [11, 12].
Reprogrammed energy metabolism is a hallmark 
of cancer cells and is rapidly emerging as a potential 
target for therapeutic intervention [13–15]. The ability 
to overcome metabolic stress is a crucial step for cancer 
cell survival and metastasis [16]. Upregulation of lipid 
synthesis has been identified as a metabolic adaptation 
that promotes cancer cell survival; however, the exact 
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mechanisms involved in this adaptation are not completely 
understood [3, 17]. Furthermore, even though there is 
clear evidence that the energy status of tumor cells is 
crucial for maintenance of the transformed phenotype and 
metastatic capabilities [18, 19], the role of FASN in the 
regulation of energy homeostasis in cancer cells is not yet 
established. Fatty acids are energy-providing substrates 
catabolized by fatty acid oxidation (FAO) [18]. Recent 
studies suggest that when cancer cells require additional 
adenosine triphosphate (ATP), FAO is critically important 
for cell survival [20–22]. However, it remains unclear 
whether cancer cells preferentially oxidize exogenously-
derived fatty acids or favor the oxidation of endogenous 
fatty acids, which are synthesized at a high rate by FASN.
To overcome metabolic stress, cancer cells activate 
several pro-survival pathways. Activation of AMP-
activated protein kinase (AMPK), an established metabolic 
stress sensor, occurs with even modest decreases in ATP 
production. This activation promotes enhanced activity of 
catabolic pathways that generate more ATP and inhibits 
anabolic pathways [23]. Autophagy also represents a 
crucial mechanism which allows tumor cells to adjust 
to changes in nutrient availability [24]. However, the 
link between autophagy and de novo lipid synthesis 
has not been established. In the present study, we test 
the hypothesis that overexpression of FASN promotes 
a switch in metabolic pathways that drives cellular 
bioenergetics along routes that support cancer cell survival 
during CRC progression. We show that overexpression of 
FASN leads to a significant increase in cellular respiration 
including enhanced FAO. Consistently, we show that 
under conditions of energy stress, high expression of 
FASN is associated with a lower level of AMPK activation 
and p62 accumulation, a marker of autophagy inhibition. 
Collectively, our data suggest that upregulation of de novo 
lipogenesis is protective to CRC cells during energy stress 
conditions and, thus, can play a crucial role in cancer 
progression and metastasis.
RESULTS
FASN regulates cellular respiration in CRC
To sustain uncontrolled proliferation and survive 
energy stress conditions during cancer progression, 
cancer cells alter their energy production [25]. To evaluate 
the effect of FASN on cellular respiration, oxygen 
consumption rate (OCR) was measured in HCT116 and 
HT29 CRC cell lines with stable knockdown of FASN and 
in SW480 cells with stable overexpression of FASN using 
the Seahorse XF Extracellular Flux Analyzer (FASN 
expression in CRC cell lines is shown in Supplemental 
Fig. 1). High levels of FASN are associated with a 
significant increase in basal response (including both 
mitochondrial and non-mitochondrial respiration) of 
CRC cell lines under standard mitochondrial stress assay 
conditions (Fig. 1A-1B). Quantification of mitochondrial 
and non-mitochondrial respiration showed that the 
lower cellular respiration in HCT116 cells with stable 
knockdown of FASN, as compared to control, is primarily 
due to a decrease in non-mitochondrial respiration of 
cells; however, knockdown of FASN in HT29 cells 
predominantly decreased mitochondrial respiration. 
Overexpression of FASN significantly increased both 
mitochondrial and non-mitochondrial respiration in 
SW480 cells (Fig. 1C-1D). Consistently, knockdown of 
FASN in HT29 cells was associated with decreased energy 
production by mitochondria, as shown by ATP turnover 
for mitochondrial respiration, whereas overexpression 
of FASN in SW480 cells increased ATP turnover. 
Interestingly, stable knockdown of FASN in HCT116 
cells, which, as we found, heavily rely on glycolysis, 
significantly increased mitochondrial turnover of ATP 
(Fig. 1E). These findings suggest a possible compensatory 
mechanism by cancer cells with reduced ATP levels to 
upregulate mitochondrial activity. We also observed an 
increase in spare respiratory capacity of mitochondria 
HCT116 and HT29 cells with knockdown of FASN, but 
no significant change in respiratory capacity was noted 
when FASN was overexpressed in SW480 cells (Fig. 1F). 
Together, these data suggest that FASN plays an important 
role in regulation of energy homeostasis in CRC.
Inhibition of FASN decreases the dependence 
of CRC cells on glycolysis
Many cancer cells rely on aerobic glycolysis for 
growth and survival [15]. To confirm our data from the 
mitochondrial stress test indicating that the glycolytic 
activity of CRC cells may depend on the level of FASN 
expression, we performed a glycolysis stress test. As 
demonstrated in Fig. 2A-2B, stable inhibition of FASN 
in HCT116 and HT29 CRC cell lines led to a significant 
decrease in glycolysis. Similar results were observed in 
KM20 cells; however, the results were not statistically 
significant (Fig. 2A-2B). Consistent with the high reliance 
of HCT116 cells on glycolysis, we found that inhibition 
of FASN significantly decreased the glycolytic capacity 
and glycolytic reserve in this cell line. In contrast, no 
difference in these parameters was observed in the 
other tested cell lines (Fig. 2C-2D). Together, these 
results suggest that upregulation of FASN contributes to 
maintaining elevated glycolysis in CRC cells.
FASN regulates the level of FAO under different 
conditions of substrate availability
Mitochondrial respiration burns glucose, fatty 
acids, and amino acids to produce usable energy [26]. 
Fatty acids are degraded in mitochondria by β-oxidation 
and oxidative phosphorylation to produce ATP [18]. 
However, it remains unknown whether cancer cells 
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preferentially oxidize endogenous fatty acids or utilize 
exogenous fatty acids as substrates for energy production. 
To test whether de novo synthesized fatty acids contribute 
to FAO, OCR was measured in cells in the absence or 
presence of etomoxir (ETO), an inhibitor of carnitine 
palmitoyltransferase-1 (CPT-1). CPT-1 is a rate-limiting 
step of the CPT system, which is required for transport of 
fatty acids to the mitochondrial matrix for oxidation [27]. 
Therefore, inhibition of CPT-1 should decrease OCR of 
cells if endogenous fatty acids are oxidized [26]. Fig. 3A 
demonstrates that stable knockdown of FASN significantly 
decreased FAO in HT29 and KM20 cells, but not in 
HCT116 cells.
To assess oxidation of exogenous fatty acids in 
control and FASN knockdown CRC cells, we utilized the 
XF Palmitate-BSA FAO substrate assay. Interestingly, 
Figure 1: Fatty acid synthase regulates cellular respiration in CRC cell lines. A. Cellular respiration of HCT116, HT29 
and SW480 cells with altered expression of FASN was analyzed by mitochondrial stress test using a Seahorse XF96 Analyzer. Oxygen 
consumption rate (OCR) was measured prior to and after injections of oligomycin (Oligo) at 1 μM working concentration, carbonyl cyanide-
4-(trifluoromethoxy) phenylhydrazone (FCCP) at 0.6 μM working concentration and combination of antimycin A and rotenone (A&R) at 
1 μM working concentration (see Materials and Methods). Representative graphs are shown. B-F. Data analysis was performed using 
Wave 2.1 (Seahorse Bioscience). Quantitative analysis demonstrates differences in B basal response (Measurements 1–3), C mitochondrial 
respiration, and D non-mitochondrial respiration (OCR after antimycin A and rotenone exposure) upon changes in expression of FASN in 
HCT116, HT29 and SW480 cell lines. E ATP turnover is expressed as a percentage of a baseline value and calculated as 100x (OCR phase 
1 - OCR phase 2) / Basal OCR in CRC cell lines. F Spare respiratory capacity is expressed as a percentage of a baseline value and calculated 
as 100x (OCR phase 3 - OCR phase 4) / Basal OCR. All experiments were performed at least twice using multiple replicates; *p < 0.05.
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supplementation of exogenous palmitate uncoupled the 
electron transport and phosphorylation reactions, and 
thus inhibited production of ATP in both control and 
FASN knockdown HCT116 cells. Furthermore, in this 
experimental setting, we observed that inhibition of FASN 
in HCT116 cells decreased oxidation of both endogenous 
fatty acids and exogenously derived palmitate as compared 
with control cells (Supplemental Fig. 2). Similar results 
were observed in HT29 cells (data not shown).
To extend investigations on the role of FASN 
in mitochondrial respiration, we measured OCR and 
quantified FAO in cells cultured with no substrate 
medium, or medium supplemented with glucose or 
glutamine. We observed a significant decrease in OCR 
and FAO in KM20 cells with stable knockdown of FASN 
cultured in basal medium or medium supplemented with 
either glucose or glutamine as compared with control cells 
(Fig. 3B). Inhibition of FASN in HCT116 cells cultured 
under similar conditions also led to a significant decrease 
in OCR, particularly when the medium was supplemented 
with glucose or glutamine (Fig. 3C). We did not see a 
significant difference in FAO in HCT116 cells with stable 
knockdown of FASN as compared to control cells cultured 
in basal medium. However, when cultured in medium 
supplemented with glucose or glutamine, HCT116 
cells with stable knockdown of FASN utilized FAO to 
a significantly less degree as compared with control 
cells (Fig. 3C). In contrast, overexpression of FASN 
in SW480 cells significantly increased OCR and FAO 
when cells were cultured in basal medium or in medium 
supplemented with either glucose or glutamine (Fig. 3D). 
Collectively, these results suggest that CRC cells, under 
a variety of substrate availabilities, efficiently oxidize de 
novo synthesized fatty acids.
Figure 2: Inhibition of FASN decreases glycolysis in CRC cells. A. Representative graphs of XF Glycolysis Stress Test using 
CRC cell lines with stable knockdown of FASN. Extracellular acidification rate (ECAR) is used as a measure of anaerobic glycolysis. 
B. Quantitative analysis of glycolysis, C. glycolytic capacity, and D. glycolytic reserve in NTC and FASNsh CRC cell lines. Data shown as 
an average of area under the curve and calculated using ANOVA and Tukey post test (XF Glycolysis Test Software). All experiments were 
performed at least twice using multiple replicates; *p < 0.05.
Oncotarget18895www.impactjournals.com/oncotarget
Overexpression of FASN significantly increases 
dependence of CRC cells on FAO in matrix-
detached conditions
Similar to glucose starvation, matrix detachment 
elicits energy stress [16, 18]. Upregulation of UCP2, a 
key regulator of mitochondrial FAO [28], observed in 
CRC cells when cultured in matrix-detached conditions, 
supports our hypothesis that CRC cells extensively utilize 
FAO under these conditions (data not shown). To elucidate 
the role of FASN in FAO and production of ATP in a 
matrix-detached condition, OCR was measured in cells 
Figure 3: FASN regulates the level of FAO under different conditions of substrate availability. OCR was measured in 
cells in the absence or presence of ETO (40 μM) using a Seahorse XF96 Analyzer. FAO was quantified as a response to ETO treatment. 
A. Changes in FAO in CRC cells with stable knockdown of FASN. Experiments performed in FAO assay medium (2.5 mm glucose, 0.5 mm 
carnitine, 5 mm HEPES). B-D. OCR and FAO of NTC and FASN knockdown KM20 B, NTC and FASN knockdown HCT116 C, and 
control and FASN overexpression SW480 D cells were measured while cells cultured on no substrate medium, medium supplemented with 
glucose (25 mM) or with glutamine (6 mM). Data analysis was performed using Wave 2.1 (Seahorse Bioscience). All experiments were 
performed at least twice using multiple replicates; *p < 0.05.
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seeded onto XF cell culture plates pre-coated with poly 
2-hydroxyethyl methacrylate (Poly-HEMA). Inhibition of 
FASN in HCT116 cells significantly decreased FAO with 
matrix detachment (Fig. 4A); in contrast, overexpression 
of FASN in SW480 cell lines significantly increased FAO 
(Fig. 4B). Consistently, the high level of FASN in these 
cell lines was associated with an increased production 
of ATP in these conditions (Fig. 4C-4D). Together, these 
results suggest that overexpression of FASN is associated 
with increased FAO in matrix-detached conditions and is 
consistent with increased production of ATP by CRC cells.
Upregulation of FASN in CRC cells is associated 
with a decrease in activity of AMPK and 
increased expression of p62
AMPK is a crucial sensor of energy status and 
is activated in response to declining fuel supply [29]. 
From a metabolic standpoint, AMPK regulates energy 
homeostasis under conditions of metabolic stress by 
activating pathways of catabolic metabolism such as 
autophagy [29, 30]. To test whether changes in the level 
of FASN expression and bioenergetic status of CRC 
cells correspond to changes in major energy-sensing 
pathways, HCT116 cells with stable knockdown of FASN 
and SW480 cells with stable overexpression of FASN 
were cultured in matrix-attached or matrix-detached 
conditions for 48 h prior to western blot analysis. Stable 
knockdown of FASN induces apoptosis in CRC cells 
cultured either in normal or serum free medium (SFM) 
for 48 h (Supplemental Fig. 3). As shown in Fig. 5A, 
stable inhibition of FASN expression in HCT116 cells is 
associated with an increased phosphorylation of AMPK 
when cells are cultured in either normal medium or SFM 
in matrix-detached conditions; in contrast, overexpression 
of FASN in SW480 cells decreased activity of pAMPK 
in these conditions. Furthermore, knockdown of FASN 
expression in HCT116 is associated with downregulation 
of p62 expression, a marker of autophagy inhibition, 
when cultured in SFM in matrix-detached conditions. 
In contrast, overexpression of FASN in SW480 cells 
led to a marked increase in expression of p62 in SFM in 
both attached and matrix-detached conditions. We also 
noted an increase in PARP cleavage in HCT116 cells 
with FASN knockdown as compared to control when 
cells were cultured in normal medium in attached and 
matrix-detached conditions or in SEM in matrix-detached 
conditions. Culturing SW480 cells with overexpression 
Figure 4: FASN overexpression significantly increases dependence of CRC cells on FAO in matrix-detached 
conditions. A. Fold change in FAO in NTC and FASN knockdown HCT116 cells in adherent and matrix-detached conditions. B. Fold 
change in FAO in control and FASN overexpression SW480 cells in adherent and matrix-detached conditions. C. Fold change in the 
production of ATP in NTC and FASN knockdown HCT116 cells in adherent and matrix-detached conditions. D. Fold change in the 
production of ATP in control and FASN overexpression SW480 cells in adherent and matrix-detached conditions. All experiments were 
performed at least twice using multiple replicates; *p < 0.05.
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of FASN under the same conditions led to a decrease in 
PARP cleavage (Fig. 5A).
To test whether the levels of other autophagy 
markers are regulated by FASN, we assessed expression of 
microtubule-associated protein 1 light chain 3 (LC3) and 
Beclin 1, the autophagosome-associated proteins [31, 32], 
by western blot analysis. As shown in Supplemental 
Fig. 4A, culturing HCT116 and SW480 cells in serum 
free, matrix-detached conditions significantly increased 
expression of Beclin1, suggesting that the combination 
of nutrient starvation and matrix-detachment induces 
autophagy; however, no significant difference in Beclin 1 
was observed due to altered expression of FASN in any 
experimental conditions. Surprisingly, analysis of LC3B 
expression, one of the isoforms of LC3 commonly used 
as an autophagy marker [31], was not consistent with 
induction of autophagy when cells were cultured in serum 
free, matrix-detached conditions; however, an increase in 
expression of this marker was observed when SW480 cells 
overexpressing FASN were cultured in normal medium. 
Interestingly, expression of LC3A, another isoform of 
LC3, was consistently induced by cell starvation or 
matrix-detachment in HCT116, HT29 and SW480 cell 
lines. Moreover, inhibition of FASN in HCT116 and 
HT29 cells significantly induced expression of LC3A, 
whereas overexpression of FASN in SW480 cells inhibited 
expression of this protein (Supplemental Fig. 4B-4C). To 
confirm these results, we assessed the level of LC3A in 
Figure 5: Upregulation of FASN in CRC cells is associated with a decrease in activity of AMPK and accumulation 
of p62. A. Western blot analysis of CRC cell lines with altered expression of FASN for pAMPK, total AMPK, p62, and cleaved PARP 
cultured in adherent and matrix-detached conditions on either normal or serum free medium for 48 h. The relative expression of pAMPK, 
cleaved PARP and p62 was quantified by normalizing band intensity to total AMPK and actin and is shown under the corresponding bands 
as a fold change between NTC vs FASNsh or control vs FASN. B. Immunofluorescent staining of tissue sections from orthotopic CRCs 
(NTC and FASNsh HCT116; NTC and FASNsh HT29) for FASN (green), p62 (red), TIP47 (red), and 4′,6-diamidino-2-phenylindole 
(DAPI) (blue). x40 magnification.
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HCT116 and HT29 cells with stable knockdown of FASN 
using confocal microscopy. As shown in Supplemental 
Fig. 4D, inhibition of FASN in HCT116 and HT29 
cells, cultured in SFM, increases expression of LC3A, 
suggesting that a decrease in expression of FASN induces 
autophagy in CRC cells.
To test whether FASN regulates expression of p62 
in vivo, we analyzed expression of p62 in orthotopic 
CRCs established by implantation of HCT116 and 
HT29 cells, control and FASN knockdown, into colonic 
submucosa of athymic mice using murine colonoscopy 
as previously described [9]. As demonstrated by double 
immunofluorescent staining for FASN and p62, stable 
inhibition of FASN in HCT116 and HT29 orthotopic 
CRCs is associated with a decrease in expression of p62 
(Fig. 5B).
Lipid droplet accumulation is a frequent 
phenomenon of cancers, including CRC [33]. We assessed 
the expression of tail-interacting protein of 47kDa (TIP47), 
a lipid droplet-associated protein, in the orthotopic CRCs. 
As shown in Fig. 5B, inhibition of FASN in HCT116 and 
HT29 orthotopic tumors is associated with a decrease 
in expression of TIP47, suggesting that inhibition of 
FASN diminishes accumulation of lipid droplets in CRC. 
Interestingly, further analysis of FASN, p62 and TIP47 
staining in orthotopic CRCs using confocal microscopy 
revealed a high degree of spectral overlap between FASN 
and p62, and FASN and TIP47, suggesting that these 
proteins may reside in close proximity or interact in CRC 
cells (Supplemental Fig. 4D).
Collectively, these results suggest that, under stress 
conditions, overexpression of FASN protects cancer cells 
by dampening signaling triggered by energy stress.
Expression of FASN significantly correlates with 
the level of p62 expression in primary CRC
We have previously demonstrated that, compared 
to normal colonic mucosa, the level of FASN expression 
is significantly higher in primary CRC and liver 
metastases [10]. Using immunohistochemical (IHC) 
analysis, expression of FASN, pAMPK and p62 was 
assessed in clinical samples, which included matched 
primary cancer, liver metastases and normal colonic 
mucosa from 19 CRC patients. Statistical evaluation of 
immunoreactivity scores showed significantly increased 
expression of FASN, pAMPK and p62 in primary CRC 
and liver metastases as compared with normal colon 
mucosa. However, no significant difference in expression 
for these markers was noted between the primary cancer 
and matching liver metastasis (Fig. 6). We also observed 
a moderate correlation between FASN and p62 that was 
statistically significant (Spearman’s r = 0.46, p = 0.049); 
no other significant correlations were noted. Western blot 
and IHC analyses of 5 additional CRC surgical specimens, 
which included primary CRC and matched normal colonic 
mucosa, were consistent with IHC analysis of clinical 
samples and showed that high expression of FASN is 
associated with an increased expression of p62 in primary 
CRC (Supplemental Fig. 5).
DISCUSSION
Overexpression of FASN has been shown to 
promote cancer growth and metastasis [9, 10, 17, 34]. 
Lipids endogenously synthesized by FASN can be utilized 
for the synthesis of phospholipids and as constituents for 
membrane biosynthesis; however, its role in providing 
substrates for energy production has not yet been 
established [26]. Here, for the first time, we provide a 
comprehensive analysis of CRC cell metabolism regarding 
its dependence on expression of FASN. First, we show 
that a high level of FASN expression can contribute to 
enhanced glycolysis and mitochondrial respiration in 
CRC. Second, we demonstrate that a high level of FASN 
expression is associated with increased FAO in CRC 
cells, particularly during metabolic-stress conditions. 
Consistently, we demonstrate that overexpression of 
FASN prevents activation of stress-sensing pathways, such 
as the AMPK signaling pathway and autophagy, and leads 
to accumulation of lipid droplets in CRC.
Recent studies have shown that, despite enhanced 
glycolysis, mitochondrial oxidative phosphorylation is 
functionally intact in most cancers, and each cancer has 
unique metabolic features [35]. Consistently, quantitative 
analysis of metabolism of CRC cell lines, presented 
in our study, revealed that their reliance on glycolysis 
and mitochondrial respiration is cell line dependent and 
most likely dependent on the genetic background and 
mutational status of the cancer cells. As an example, the 
analysis of cellular respiration in HCT116 and HT29 
demonstrates that HCT116 cells predominantly rely on 
non-mitochondrial respiration including glycolysis as 
compared to HT29 cells, which are highly dependent 
on the mitochondrial pathway for production of ATP. 
Furthermore, we noted that a decrease in glycolysis due 
to inhibition of FASN in HCT116 increases mitochondrial 
respiration, thus providing evidence of the interplay 
between these energy pathways. The utilization of FAO 
by HCT116 cells in the presence of glucose and glutamine 
further supports the metabolic flexibility of cancer cells 
to adapt the mechanisms of energy production to changes 
in the substrate availability. Interestingly, despite the 
genetic and metabolic diversity of cell lines used in 
this study and, inhibition of FASN led to a significant 
decrease in cellular respiration in all cell lines, whether 
due to inhibited glycolysis, mitochondrial respiration, or 
both, suggesting that inhibition of de novo lipogenesis 
would have a beneficial effect in a wide range of tumors. 
The effect of FASN in sustaining an elevated glycolytic 
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activity of cancer cells can be explained by several 
mechanisms. First, it is possible that lipid synthesis-
derived NADP+ could help to increase the availability of 
cytosolic NAD+ required to maintain glycolysis [33, 36]. 
Furthermore, limited mitochondrial ATP production can 
impair glycolytic ATP synthesis through a decrease in the 
mitochondria-bound hexokinase activity [26]. Therefore, 
the decrease in glycolysis observed in HT29 and KM20 
cells with stable inhibition of FASN could be a secondary 
effect mediated by a decrease in ATP production in 
mitochondria. Additional investigation is required to fully 
understand the FASN-mediated mechanisms that regulate 
glycolytic activity in CRC cells.
Fatty acids represent an important energy source 
which produce twice as much ATP as carbohydrates [18]. 
The previous dogma that concurrent activities of fatty 
acid synthesis (FAS) and FAO are incompatible has been 
revised by discoveries that FAS and FAO can function 
both simultaneously and independently from each other 
[16, 18, 37]. In the present study, we demonstrate that 
upregulation of FASN enhances the activity of FAO 
and increases production of ATP, particularly during 
metabolic stress. In agreement with these findings, recent 
studies suggest that FAO may be crucial to support 
cancer cell survival during periods of energy stress 
[21, 22]. Furthermore, activation of FAO is implicated in 
maintaining cancer cell viability, production of ATP, and 
resistance to oxidative stress in glioblastoma cells [26] 
and is a key mechanism of pancreatic cell survival during 
tumor relapse [38].
Figure 6: Expression of FASN significantly correlates with expression of p62 in primary CRC. Expression of FASN, 
pAMPK, and p62 was analyzed in human tissues (matching primary CRC, liver metastasis, and normal colon), n = 19, using IHC. 
Immunoreactivity score was determined by multiplication of the values for staining intensity (0, no staining; 1, weak staining; 2, moderate 
staining; 3, strong staining) and the values for percentage of positive tumor cells (0, no positive cells; 1, 0–10% positive; 2, 11–50% 
positive; 3, 51–100% positive); *p < 0.001 as compared to normal tissue.
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Glucose-derived carbon is considered the primary 
source for de novo lipid synthesis [26]. Similarly, cancer 
cells are extremely sensitive to glutamine deprivation; 
therefore, glutamine could be a significant contributor to 
FAS [39]. Consistently, our results show that inhibition 
of FASN in CRC cells cultured on different substrates 
leads to a decrease in cellular respiration including 
FAO, thus confirming that both glucose and glutamine 
contribute to de novo lipogenesis in CRC even though 
the efficiency of utilization of these substrates is cell 
line dependent. We also investigated whether the level 
of FASN expression regulates oxidation of exogenously 
derived fatty acids. Using fluorescently labeled palmitate, 
we found no change in uptake of exogenous fatty acids 
when expression of FASN was inhibited (data not shown); 
however, FASN knockdown in HCT116 and HT29 cells 
prevented oxidation of both endogenous and exogenous 
fatty acids. We did not investigate the mechanism behind 
this phenomenon in the present study, but our recent data 
suggest that stable inhibition of FASN in CRC cells may 
change the expression of proteins, such as CPT-1, which 
are involved in transport of fatty acids to mitochondria 
and regulated by intermediate substrates of de novo 
lipogenesis [40].
Cancer cells have multiple systems to sense energy 
balance and can modify signaling pathways to ensure 
survival under conditions of metabolic stress [13]. 
The pharmacological inhibition of FASN with C93, a 
synthetic FASN inhibitor, causes rapid energy depletion 
and activation of AMPK, which leads to cytotoxicity, 
in ovarian cancer cells [41]. Consistently, results of our 
present study support the hypothesis that overexpression 
of FASN is protective during metabolic stress by satisfying 
the energy demand necessary for CRC cells to survive and 
support their functions. Activation of AMPK in FASN 
knockdown CRC cells indicates that these cells are under 
more stress than control cells. In contrast, CRC cells with 
overexpression of FASN appear to be exposed to less 
stress as indicated by the lower level of phosphorylated 
AMPK. Interestingly, AMPK is also known as a negative 
regulator of glycolysis [29]. Therefore, low AMPK 
activity in CRC cells with high FASN expression might 
also explain the increased glycolysis in these cells. 
A recent study shows that pharmacological activation 
of AMPK suppresses de novo lipogenesis in prostate 
cancer [42], suggesting the role of AMPK as an upstream 
regulator of lipid synthesis. Since both FASN and AMPK 
have been actively evaluated as targets for cancer therapy 
in pre-clinical and clinical trials, a better understanding 
of the interconnection between these proteins is necessary 
in order to develop more advanced therapeutic strategies.
p62 was identified as one of the specific substrates 
that is degraded during autophagy [43, 44]. In this study, 
we identified a novel link between de novo lipogenesis and 
p62, showing that overexpression of FASN is associated 
with p62 accumulation not only in CRC cell lines exposed 
to metabolic stress, but also in orthotopic human CRCs in 
vivo and in clinical samples. We identified a moderate but 
significant correlation between FASN and p62 expressions 
in primary CRC. In agreement with our study, increased 
accumulation of p62 was associated with aggressive 
clinicopathologic features and an unfavorable prognosis 
in oral squamous cell carcinoma [45] and in lung 
adenocarcinoma [46]. Analysis of the correlation between 
FASN and p62 expression in liver metastases did not reach 
statistical significance suggesting that an increased sample 
size should be considered in future evaluations.
The connection between autophagy and p62 
is complex and, in some cases, conflicting. Despite 
our observation that an increase in accumulation of 
p62 is associated with a decrease of expression of the 
autophagosomal marker, LC3A, and with a significant 
increase in lipid droplets, thus supporting the model that 
overexpression of FASN is associated with autophagy 
inhibition, a comprehensive investigation is required 
to better understand the role of FASN in autophagy. 
Furthermore, recent studies demonstrate that, in addition 
to autophagy, p62 plays a crucial role in a number of 
cellular processes related to malignant transformation 
and tumor progression [43, 47]; therefore, FASN-
induced accumulation of p62 may also be independent of 
autophagy in the progression of CRC. We are currently 
pursuing studies to further define the role of FASN-
mediated upregulation of p62 in CRC.
In summary, this study is the first to provide insight 
into metabolic changes that occur in cancer cells upon 
upregulation of de novo lipogenesis. Importantly, we have 
shown that endogenously synthesized FASN lipids are 
utilized for β-oxidation in CRC cells, particularly under 
energy stress conditions, suggesting that activation of 
FASN can be a crucial mechanism that sustains cancer 
cell survival and prevents cell death during progression 
of CRC and metastasis. FAO has been implicated in drug 
resistance, protection from oxidative stress, inhibition of 
pro-apoptotic pathways, supplementation of metabolic 
intermediates for cell growth, and in tumor relapse 
[18, 38]. Therefore, inhibition of de novo lipogenesis may 
represent a potential strategy for overcoming resistance 
to chemotherapeutic agents and radiation, and also as a 
possible preventative treatment for metastatic CRC.
MATERIALS AND METHODS
Cell lines
CRC lines HCT116, HT29, KM20 and SW480 
were authenticated November 2011 (Genetica DNA 
Laboratories, Cincinnati, OH). Stable FASN knockdown 
CRC cell lines were established and lipid biosynthesis 
was assessed as previously described [10]. FASN cDNA 
(ID6172538, Open Biosystem, Chicago, IL) was cloned 
into the pEGFP vector. Stable overexpression was 
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established by transfecting SW480 cells with PEGFP-
FASN vector with Gentamicin (Invitrogen, Austin, TX) 
selection as previously described [9].
Measurement of cellular oxygen consumption 
rate, extracellular acidification rate, and FAO 
using the XF96 extracellular flux analyzer
Cellular oxygen consumption rate and extracellular 
acidification rate (ECAR) were used to monitor basal 
respiration, mitochondrial respiration, glycolysis, and FAO 
in real time. Cell concentrations for XF96 plates (Seahorse 
Bioscience, North Billerica, MA) varied by cell type: 
HCT116 was 1.5 × 104 cells/well; SW480 was 2.0 × 104 
cells/well; HT29 was 3.0 × 104 cells/well; and, KM20 
was 4.0 × 104 cells/well. Plated cells were maintained 
for 24 h in a 37°C/5% CO2 incubator. One hour prior to 
assay, cells were equilibrated with bicarbonate-free low 
buffered DMEM medium without any supplement, or 
supplemented with glucose or glutamine as indicated, 
in a 37°C non-CO2 incubator. Reagents required for the 
experimental protocol were prepared in assay medium, 
loaded into reservoirs and automatically injected into 
plates as required for each assay.
XF Cell mito stress test
Experimental design followed the protocol provided 
by Seahorse Bioscience. Briefly, cells were metabolically 
perturbed by the addition of three different compounds in 
succession and the OCR was measured prior to and after 
injection of each compound. First, cells were injected 
with oligomycin (1 μM working concentration), which 
inhibits ATP synthesis and identifies the percentage of 
OCR devoted to ATP synthesis. The second compound, 
carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP) (0.6 μM working concentration), an uncoupling 
agent, collapses the mitochondrial membrane potential; 
a rapid consumption of energy and oxygen without 
ATP generation follows. FCCP was used to calculate 
the maximum and spare respiratory capacity of cells. 
Finally, cells were exposed to a combination of rotenone, 
a complex I inhibitor, and antimycin A, a complex III 
inhibitor (1 μM working concentration). This combination 
inhibits mitochondrial respiration and allows calculation 
of the mitochondrial and non-mitochondrial fractions 
contributing to respiration.
XF glycolysis stress test
For the first ECAR assessment, non-glycolytic 
acidification was obtained in the absence of extracellular 
glucose and pyruvate. Next, cells were exposed to three 
compounds, with measurements after each injection. 
The first injection, a saturating concentration of glucose 
(10 mM), causes an increase in ECAR and defines the rate 
of glycolysis under basal conditions. The second injection, 
oligomycin (1 μM working concentration), inhibits 
mitochondrial respiration and shifts energy production 
toward glycolysis, revealing the maximum glycolytic 
capacity of the cells. The final injection, 2-deoxy-D-
glucose (2-DG; 100 mM), a glucose analog, inhibits 
glycolysis. The difference between glycolytic capacity 
(Measurement 2) and glycolysis (Measurement 1) defines 
the glycolytic reserve.
Fatty acid oxidation (FAO)
Fatty acid oxidation was determined by monitoring 
the OCR of cells with no exogenous glucose or glutamine 
and by using a specific FAO inhibitor, etomoxir (40 μM). 
FAO was quantified as a response to ETO treatment as 
previously described [26]. The XF Palmitate - BSA FAO 
substrate (Seahorse Bioscience) was used to determine 
the ability of cells to oxidize exogenously added fatty 
acids, and the proportion of respiration that is supported 
by exogenous fatty acids. The substrates were prepared 
and experiments performed according the manufacturer’s 
protocol (part #102720-100 Seahorse Bioscience). For 
measurement of OCR and FAO in suspension culture, 
XF96 cell culture plates were coated with Poly-HEMA 
(Sigma Cat #P3932), and cells added at 5.0 × 104 cells/
well in assay medium 4 h prior to the experiment.
Analysis of results utilized XFe Wave Software 
(Seahorse Bioscience). Cellular protein levels, determined 
by using Piercetm BCA protein assay kit following standard 
procedure, were obtained for each well, and all data were 
normalized to protein content. Additional information 
about assays is available on the Seahorse Bioscience 
website: http://www.seahorsebio.com
Cellular ATP measurements
The levels of ATP in CRC cells with altered 
expression of FASN were assessed using ATP colorimetric 
assay according to the manufacturer’s protocol (#K354-
100, BioVision, Milpitas, CA).
Human tissues analysis
Human CRC and matching normal colonic tissues 
were obtained from consented patients at the Markey 
Cancer Center. Tissues collected from the Surgical 
Pathology Laboratory after surgical resection were 
immediately processed and then analyzed by western blot 
analysis and/or IHC.
Immunohistochemistry
Nineteen clinical specimens of primary CRC with 
matching normal colonic mucosa and liver metastases were 
analyzed for expression of FASN (Cell Signaling, # 3180), 
p62 (Abcam, ab56416) and pAMPK (Cell Signaling, # 2535). 
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Blind scoring performed by a pathologist used a semi-
quantitative method. The extent of expression score was 
assessed on a scale of 0 to 3 (no positive cells = 0, <10% = 1, 
10%–50% = 2, positive staining of >50% = 3); the intensity 
score was also measured on a scale of 0 to 3 (negative = 0, 
weak = 1, moderate = 2, strong = 3). Multiplication of the 
values for intensity and extent of expression provided a 
score for immunoreactivity.
Statistical analysis
Descriptive statistics and bar graphs summarize 
the following endpoints: OCR, ECAR, FAO, and ATP 
levels. Comparisons of non-treated control (NTC) vs. 
FASNsh groups used a two-sample t-test or ANOVA. 
Statistical analyses were performed using SAS 9.3. Data 
provided in Fig. 2 is an average of area under the curve, 
and calculated using ANOVA and Tukey post test (the XF 
Glycolysis Stress Test Software, Seahorse Bioscience). 
Paired tests using the Wilcoxon signed rank test were 
employed to assess differential expression of ordinal 
biomarker immunoreactivity scores between matched 
normal versus tumor and normal versus metastatic tissues. 
The correlations between biomarkers were measured using 
Spearman’s correlation coefficient.
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